Empowered Patient Podcast

Tim Dyer is the Co-Founder and CEO of Addex Therapeutics, which is focusing on the pharmacology known as allosteric modulation. This emerging class of small molecule drugs known as allosteric modulators is being explored for treating central nervous system and neurologic disorders, particularly movement disorders like dyskinesia associated with Parkinson's and dystonia. Addex did not invent allosteric modulation but is pioneering the screening technologies to find these difficult to locate molecules.

Tim explains, "In the conventional world, which people probably know a lot about, are the orthosteric agonists and antagonists. These molecules are binding to the active site. The way to understand, in simple terms, the difference between an allosteric and an orthosteric drug is to use an analogy of the dimmer light switch."

"If you think about the dimmer light switch, you're initially turning the light on-- that would be the orthosteric agonist. Turning the light off would be the orthosteric antagonist, and what Addex is, is the dimmer. We leave the body in charge of turning the light on, so to speak, and then the Addex, allosteric modulator, if it's a positive modulator, we are really turning up the intensity of the light. If it is a negative modulator, we are turning down the intensity, so we're really modulating the intensity of the signal."

@AddexPharma #AllostericModulators #CNSDrugDiscovery #NeurologicDrugDiscovery #DrugDevelopment #ParkinsonsDisease #Dyskinesia #Dystonia #Blepharospasm #MovementDisorders

Addextherapeutics.com

Listen to the podcast here

Tim Dyer is the Co-Founder and CEO of Addex Therapeutics, which is focusing on the pharmacology known as allosteric modulation. This emerging class of small molecule drugs known as allosteric modulators is being explored for treating central nervous system and neurologic disorders, particularly movement disorders like dyskinesia associated with Parkinson's and dystonia. Addex did not invent allosteric modulation but is pioneering the screening technologies to find these difficult to locate molecules.

Tim explains, "In the conventional world, which people probably know a lot about, are the orthosteric agonists and antagonists. These molecules are binding to the active site. The way to understand, in simple terms, the difference between an allosteric and an orthosteric drug is to use an analogy of the dimmer light switch."

"If you think about the dimmer light switch, you're initially turning the light on-- that would be the orthosteric agonist. Turning the light off would be the orthosteric antagonist, and what Addex is, is the dimmer. We leave the body in charge of turning the light on, so to speak, and then the Addex, allosteric modulator, if it's a positive modulator, we are really turning up the intensity of the light. If it is a negative modulator, we are turning down the intensity, so we're really modulating the intensity of the signal."

@AddexPharma #AllostericModulators #CNSDrugDiscovery #NeurologicDrugDiscovery #DrugDevelopment #ParkinsonsDisease #Dyskinesia #Dystonia #Blepharospasm #MovementDisorders

Addextherapeutics.com

Download the transcript here

Erica Jain is the Co-Founder and CEO of Healthie, a software as a service (SaaS) platform and family of APIs that allow healthcare providers to move more easily to a digital environment to interact with patients.

Erica explains, "Healthie serves organizations in over 25 specialties and verticals and healthcare. We got started in the nutrition and behavioral health space, and we have thousands of dietitians and health coaches that use our platform to deliver longitudinal care. We also work with digital healthcare startups, universities, and grocery stores, all of whom are popping up in scaling these virtual first experiences."

"The beauty of the problem that we solve is that companies are able to come to us, save two years and millions of dollars to prop up and scale the virtual care delivery. And by virtue of us having both an out-of-the-box solution, but coupling that with an API first experience means that really, we're able to see our organizations get started with us, experiment with us, and figure out how they want to deliver clinical care and clinical outcomes. They can also leverage our API to create, over time, those pixel-perfect experiences that they want to deliver to their clients."

@GetHealthie @EricaAJain #DigitalHealth #MedTech #SaaS #VirtualCare #Startups #Healthcare

gethealthie.com

Listen to the podcast here

Erica Jain is the Co-Founder and CEO of Healthie, a software as a service (SaaS) platform and family of APIs that allow healthcare providers to move more easily to a digital environment to interact with patients.

Erica explains, "Healthie serves organizations in over 25 specialties and verticals and healthcare. We got started in the nutrition and behavioral health space, and we have thousands of dietitians and health coaches that use our platform to deliver longitudinal care. We also work with digital healthcare startups, universities, and grocery stores, all of whom are popping up in scaling these virtual first experiences."

"The beauty of the problem that we solve is that companies are able to come to us, save two years and millions of dollars to prop up and scale the virtual care delivery. And by virtue of us having both an out-of-the-box solution, but coupling that with an API first experience means that really, we're able to see our organizations get started with us, experiment with us, and figure out how they want to deliver clinical care and clinical outcomes. They can also leverage our API to create, over time, those pixel-perfect experiences that they want to deliver to their clients."

@GetHealthie @EricaAJain #DigitalHealth #MedTech #SaaS #VirtualCare #Startups #Healthcare

gethealthie.com

Download the transcript here

Eric Adams is the CEO and President of InMed Pharmaceuticals, exploring the benefits of rare cannabinoids from the cannabis plant. We have these naturally occurring cannabinoids in our body and a number of receptors throughout our body that respond to this class of compounds. Because these rare cannabinoids exist in low quantities in the plant, they have been hard to isolate or extract, which has limited research into their therapeutic value. InMed has developed ways to economically manufacture bioidentical compounds and investigate potential benefits for treating eye and skin disorders.

Eric elaborates, "InMed Pharmaceuticals is a global leader in the manufacturing, clinical development, and commercialization of non-intoxicating, rare cannabinoids. We have two branches to the company. One is the pharmaceutical drug development program where we're taking the traditional clinical trial, FDA pathway approach to bringing important medicines to market for hard t treat diseases. On the other hand, we also have a group that is manufacturing rare cannabinoids for the health and wellness space, so things that will be sold over the counter, such as the CBD mark t, for instance. Those two sides are joined by manufacturing know-how and a general understanding of this class of compounds that we call rare cannabinoids."

@InMedPharma #cannabinoids #rarecannabinoids #rarecannabinoid #cannabinol #CBN #glaucoma #minorcannabinoids #ophthalmology #epidermolysisbullosa #rarediseases #science #pharma

InMedPharma.com

Listen to the podcast

Eric Adams is the CEO and President of InMed Pharmaceuticals, exploring the benefits of rare cannabinoids from the cannabis plant. We have these naturally occurring cannabinoids in our body and a number of receptors throughout our body that respond to this class of compounds. Because these rare cannabinoids exist in low quantities in the plant, they have been hard to isolate or extract, which has limited research into their therapeutic value. InMed has developed ways to economically manufacture bioidentical compounds and investigate potential benefits for treating eye and skin disorders.

Eric elaborates, "InMed Pharmaceuticals is a global leader in the manufacturing, clinical development, and commercialization of non-intoxicating, rare cannabinoids. We have two branches to the company. One is the pharmaceutical drug development program where we're taking the traditional clinical trial, FDA pathway approach to bringing important medicines to market for hard t treat diseases. On the other hand, we also have a group that is manufacturing rare cannabinoids for the health and wellness space, so things that will be sold over the counter, such as the CBD mark t, for instance. Those two sides are joined by manufacturing know-how and a general understanding of this class of compounds that we call rare cannabinoids."

@InMedPharma #cannabinoids #rarecannabinoids #rarecannabinoid #cannabinol #CBN #glaucoma #minorcannabinoids #ophthalmology #epidermolysisbullosa #rarediseases #science #pharma

InMedPharma.com

Download the transcript here

Natasha Drapeau is the Executive Vice President of BioSig Technologies, pioneers in advanced biomedical signal processing solutions that will unlock the future of bioelectronic medicine, starting with the PURE EP™ System and their work on common and complex cardiac arrhythmia. Approximately more than half of patients diagnosed with this heart rhythm disorder have AFib. The BioSig noninvasive technology works with all the systems generating data to get an entire cardiac picture for diagnosis and performing a cardiac ablation procedure.

Natasha explains, "What we're focusing on with our technology is really to prevent that signal distortion. That's happening both through our different hardware architecture and the software algorithms. We focus on delivering a much cleaner, more detailed cardiac picture displayed to the physician in real-time."

"But also, we're uncovering a lot of diagnostic data that was simply not there before. We have side-by-side comparisons because we have other technology in support at the same time as PURE EP. I believe we have an opportunity there to give that better, more comprehensive cardiac picture to physicians, and that could lead to a transformation of care."

@BioSig_Tech #MedTech #MedicalTechnology #Afib #AtrialFibrillation #AfibAwareness #Electrophysiology #Epeeps #GlobalEP #AF #Ablation #Cardiology #CardioTwitter #HeartHealth #BioelectronicMedicine

BioSig.com

Listen to the podcast here

Natasha Drapeau is the Executive Vice President of BioSig Technologies, pioneers in advanced biomedical signal processing solutions that will unlock the future of bioelectronic medicine, starting with the PURE EP™ System and their work on common and complex cardiac arrhythmia. Approximately more than half of patients diagnosed with this heart rhythm disorder have AFib. The BioSig noninvasive technology works with all the systems generating data to get an entire cardiac picture for diagnosis and performing a cardiac ablation procedure.

Natasha explains, "What we're focusing on with our technology is really to prevent that signal distortion. That's happening both through our different hardware architecture and the software algorithms. We focus on delivering a much cleaner, more detailed cardiac picture displayed to the physician in real-time."

"But also, we're uncovering a lot of diagnostic data that was simply not there before. We have side-by-side comparisons because we have other technology in support at the same time as PURE EP. I believe we have an opportunity there to give that better, more comprehensive cardiac picture to physicians, and that could lead to a transformation of care."

@BioSig_Tech #MedTech #MedicalTechnology #AFib #AtrialFibrillation #AfibAwareness #Electrophysiology #Epeeps #GlobalEP #AF #Ablation #Cardiology #CardioTwitter #HeartHealth #BioelectronicMedicine

BioSig.com

Download the transcript here

Sylvia Hastanan is the CEO and Founder of Greater Good Health and shines a light on the experience and new skills that nurse practitioners have developed as a result of the demand for virtual care during the pandemic. Sylvia wants to empower and train NPs as primary care providers to provide more access to underserved communities and to promote a stronger partnership between nurse practitioners and physicians to handle the ever-increasing demand for chronic and senior healthcare.

Sylvia explains, "Greater Good Health is building a medical group of nurse practitioners simply with a mission to expand more access to care to people who need it. We believe in supporting nurse practitioners, who we think have been an overlooked and maybe underutilized resource in healthcare, and nurse practitioners specifically as primary care providers."

"Well, my background has always been in healthcare and provider services. I worked for organizations across the United States that supported physician groups, primary care physician groups specifically. And I watched as NPs worked alongside physicians. I watched as physicians continued to be burnt out and struggled with caseloads, patient caseloads, and 35 patients in a day and only seeing them for minutes at a time."

#GGH #GreaterGoodHealth #NursePractitioner #NP #Healthcare #COVID #Pandemic

GreaterGoodHealth.com

Listen to the podcast here

Sylvia Hastanan is the CEO and Founder of Greater Good Health and shines a light on the experience and new skills that nurse practitioners have developed as a result of the demand for virtual care during the pandemic. Sylvia wants to empower and train NPs as primary care providers to provide more access to underserved communities and to promote a stronger partnership between nurse practitioners and physicians to handle the ever-increasing demand for chronic and senior healthcare.

Sylvia explains, "Greater Good Health is building a medical group of nurse practitioners simply with a mission to expand more access to care to people who need it. We believe in supporting nurse practitioners, who we think have been an overlooked and maybe underutilized resource in healthcare, and nurse practitioners specifically as primary care providers."

"Well, my background has always been in healthcare and provider services. I worked for organizations across the United States that supported physician groups, primary care physician groups specifically. And I watched as NPs worked alongside physicians. I watched as physicians continued to be burnt out and struggled with caseloads, patient caseloads, and 35 patients in a day and only seeing them for minutes at a time."

#GGH #GreaterGoodHealth #NursePractitioner #NP #Healthcare #COVID #Pandemic

GreaterGoodHealth.com

Download the transcript here